Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_2
1
33%
Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Other(1)

Detailed Status

Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (33.3%)
N/A2 (66.7%)

Trials by Status

recruiting267%
unknown133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingnot_applicable

A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer

NCT06451445
recruitingnot_applicable

Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer

NCT04276857
unknownphase_2

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

NCT01835977

Clinical Trials (3)

Showing 3 of 3 trials
NCT06451445Not Applicable

A Pan-Canadian, Investigator Initiated Clinical Trial With Focal IRE Directed to Intermediate-Risk Prostate Cancer

Recruiting
NCT04276857Not Applicable

Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer

Recruiting
NCT01835977Phase 2

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3